STOCK TITAN
  1. Home
  2. News
  3. AGLE

Aeglea BioTherapeutics Inc - agle STOCK NEWS

Welcome to our dedicated news page for Aeglea BioTherapeutics (Ticker: agle), a resource for investors and traders seeking the latest updates and insights on Aeglea BioTherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aeglea BioTherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aeglea BioTherapeutics's position in the market.

News
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD
Rhea-AI Summary
Spyre Therapeutics, Inc. (SYRE) will begin trading on Nasdaq under the ticker symbol 'SYRE' effective November 28, 2023. The company aims to develop a next-generation of Inflammatory Bowel Disease (IBD) products by enhancing efficacy and convenience of therapies. With $205 million in cash, cash equivalents, marketable securities, and restricted cash as of September 30, 2023, Spyre has expected runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.79%
Tags
management
-
News
Aeglea BioTherapeutics Announces Grants of Inducement Awards
Rhea-AI Summary
Aeglea BioTherapeutics, Inc. (AGLE) announced the approval of stock options and restricted stock units as equity inducement awards for non-executive employees, under the 2018 Equity Inducement Plan. The grants include 351,750 shares of common stock and 18,912 restricted stock units, with a 10-year term and an exercise price of $10.48 per share. The options and units will vest over time, subject to continuous service with Aeglea.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Aeglea BioTherapeutics, Inc. (AGLE) announced progress in their IBD portfolio, with SPY001 and SPY002 on track for IND filings in 2024. The company also strengthened its leadership team, has $205 million in cash, and expects to complete a stockholder vote on November 21.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
earnings
News
Aeglea BioTherapeutics Announces Grants of Inducement Awards
Rhea-AI Summary
Aeglea BioTherapeutics, Inc. has announced the approval of stock options for six non-executive employees. The options allow the purchase of an aggregate of 729,600 shares of common stock at an exercise price of $11.43 per share. The options will vest over time, with one-fourth of the shares becoming exercisable on the first anniversary of each employee's start date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences
Rhea-AI Summary
Aeglea BioTherapeutics, Inc. (AGLE) will participate in upcoming investor conferences to present their pipeline of antibody therapeutics for inflammatory bowel disease. The conferences include Guggenheim 5th Annual Inflammation & Immunology Conference, Stifel 2023 Annual Healthcare Conference, and Jefferies 2023 London Healthcare Conference. Webcasts of the presentations can be accessed on the Aeglea website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences
-
News
Aeglea BioTherapeutics Announces Grants of Inducement Awards
Rhea-AI Summary
Aeglea BioTherapeutics grants stock options to non-executive employees, totaling 2.9M shares, with a 10-year term and an exercise price of $11.70 per share. Options vest and become exercisable over time, subject to continuous service with Aeglea.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.42%
Tags
none
News
Aeglea BioTherapeutics to Participate in Upcoming September Conference
Rhea-AI Summary
Aeglea BioTherapeutics to participate in Stifel 2023 Immunology & Inflammation Virtual Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
conferences
-
News
Aeglea BioTherapeutics Announces Reverse Stock Split
Rhea-AI Summary
Aeglea BioTherapeutics, Inc. (AGLE) announces a 1-for-25 reverse stock split to meet Nasdaq listing price per share requirements, reducing authorized shares from 500 million to 20 million. The split will take effect on September 8, 2023, and aims to transform the treatment of inflammatory bowel disease with its pipeline of antibody therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2402.92%
Tags
none
-
News
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
Rhea-AI Summary
Aeglea BioTherapeutics announces the appointment of Scott Burrows as CFO and Heidy Abreu King-Jones as Chief Legal Officer and Corporate Secretary. The appointments strengthen Aeglea's leadership team as they advance their inflammatory bowel disease portfolio. Jonathan Alspaugh, current President and CFO, will transition into a strategic advisory role. Mr. Burrows brings over two decades of experience in biopharma finance leadership roles, while Ms. King-Jones has a proven track record in legal and corporate roles in the biopharma industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
management
News
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Aeglea BioTherapeutics, Inc. (AGLE) announced the acquisition of Spyre Therapeutics' assets and an oversubscribed $210.0 million private investment, positioning the company to advance its inflammatory bowel disease (IBD) portfolio. The sale of legacy pipeline candidate, pegzilarginase, streamlines operations and increases focus on IBD strategy. As of June 30, 2023, the company had $236.7 million in cash and cash equivalents and restricted cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
earnings
Stock AGLE logo
Aeglea BioTherapeutics Inc

Nasdaq:AGLE

AGLE Rankings

N/A Ranked by Market Cap
#4882 Ranked by Stock Gains
N/A Ranked by Dividends

AGLE Stock Data

48.63M
1.92M
3.45%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Austin

About AGLE

aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f